US EditionKedrion Raises Awareness Around Plasminogen Deficiency
- On May 5, 2025, Kedrion Biopharma organized a series of worldwide events—including online and face-to-face activities—to highlight the challenges of Plasminogen Deficiency .
- This campaign comes after Plasminogen Deficiency Awareness Day on May 4, an annual initiative aimed at raising understanding of PLGD-1, its symptoms, and the value of early detection.
- PLGD-1 is an uncommon inherited condition, occurring in about 1.6 individuals per million, that results in abnormal fibrin-rich deposits on mucous membranes and, if not diagnosed or managed, can cause serious complications such as impaired sight and hearing, breathing difficulties, or reproductive challenges.
- Known cases number fewer than 500 in the US and 12,000 globally, and Kedrion, the producer of the only FDA-approved treatment, stressed the importance of raising understanding and promoting early diagnosis via a straightforward lab test.
- Kedrion’s global events united physicians, patients, and stakeholders sharing impactful stories, while advocacy leaders praised the company's efforts highlighting the ongoing challenges and community growth.
Insights by Ground AI
Does this summary seem wrong?
36 Articles
36 Articles
All
Left
5
Center
11
Right
1
InsideNoVA.com+35 Reposted by 35 other sources
Kedrion Raises Awareness Around Plasminogen Deficiency
FORT LEE, N.J., May 5, 2025 /PRNewswire/ -- Kedrion Biopharma is raising awareness for Plasminogen Deficiency (PLGD-1) with virtual, digital and in person events throughout the day on May 5. PLGD-1 is a rare genetic disorder affecting approximately 1.6 in…
Coverage Details
Total News Sources36
Leaning Left5Leaning Right1Center11Last UpdatedBias Distribution65% Center
Bias Distribution
- 65% of the sources are Center
65% Center
L 29%
C 65%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
